Key facts
- Tandem Health raised $50 million in Series A funding, led by Kinnevik.
- The funding will be used to expand Tandem's AI-native operating system for clinical workflows.
- Tandem's AI assistant generates clinical notes from patient consultations.
- Over 200,000 NHS professionals in the UK have access to Tandem's technology through a partnership with Accurx.
- Tandem operates in the UK, Germany, France, Spain, and Nordic countries.
Tandem Health, a Stockholm-based healthtech company, has secured $50 million in Series A funding to advance its AI-native operating system for clinical workflows. The funding round was led by Kinnevik, with participation from Northzone, Amino Collective, and Visionaries Club. This investment aims to accelerate Tandem's growth across Europe and enhance its AI capabilities, particularly within the UK's National Health Service (NHS).
Tandem Health's core offering is an AI assistant that listens to patient consultations, transcribes them, and automatically generates draft medical notes, reducing administrative burdens for clinicians. The company reports that tens of thousands of clinicians across Europe, including in the UK, Germany, France, and Spain, already use its technology. In the UK, a partnership with Accurx has provided access to Tandem's AI scribe for over 200,000 NHS professionals, making it one of the largest AI scribe deployments globally.
The company plans to use the new funding to expand its AI-native operating system beyond clinical documentation to support other aspects of the clinical workflow, such as capturing clinical codes, coordinating care, and assisting with decisions at the point of need. Tandem emphasizes its commitment to supporting healthcare workers by removing friction, rather than replacing them. The investment will also support the expansion of its UK-based clinical team and enhance interoperability with key electronic patient record systems used within the NHS.